IM Therapeutics Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 5

Employees
  • Latest Deal Type

  • Series A

  • Latest Deal Amount

  • $7M

  • Investors

  • 3

IM Therapeutics General Information

Description

Developer of a biotechnology platform designed to build drug molecules for specific blockade of an HLA protein in a given autoimmune disease. The company's platform screens millions of compounds for optimal docking within HLA proteins together with rational drug design and bioassays to develop targeted therapeutic candidates, enabling patients and the medical community to get access to a broad pipeline of drugs against HLA targets in autoimmune disorders including celiac disease.

Contact Information

Website
www.imtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 12635 East Montview Boulevard
  • Suite 128
  • Aurora, CO 80045
  • United States
+1 (303) 000-0000

IM Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IM Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 30-Oct-2020 $7M 000.00 Completed Generating Revenue
3. Early Stage VC (Series A) 09-Oct-2019 0000 000.00 Completed Startup
2. Angel (individual) 03-Aug-2016 $350K $850K Completed Startup
1. Angel (individual) 30-Jun-2015 $500K $500K Completed Startup
To view IM Therapeutics’s complete valuation and funding history, request access »

IM Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biotechnology platform designed to build drug molecules for specific blockade of an HLA protein in a give
Drug Discovery
Aurora, CO
5 As of 2023
000.00
00000000000 000.00

000000

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000 000000000
Cambridge, MA
000
00.00 0000-00-00
00000000000 000

000000

abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Cambridge, MA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

IM Therapeutics Competitors (66)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
00000000 Venture Capital-Backed Paris, France 00 00000 00000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Waltham, MA 00 000.00 00000000000 000.00
You’re viewing 5 of 66 competitors. Get the full list »

IM Therapeutics Patents

  • 14

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

IM Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220194893-A1 Methods for producing d-alpha-methyldopa Pending 23-Dec-2020 0000000000 0
US-20220204471-A1 Compounds and methods for treating autoimmune disorders by targeting hla-dq2 Pending 22-Dec-2020 00000000000
US-20220055994-A1 Compounds and methods for treating autoimmune disorders by targeting hla-dq2 Pending 21-Aug-2020 0000000000
US-11013707-B2 Administration of oral methyldopa Active 23-Mar-2018 0000000000
US-20190290607-A1 Administration of oral methyldopa Active 23-Mar-2018 A61K31/195
To view IM Therapeutics’s complete patent history, request access »

IM Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Nandan Padukone Ph.D Chief Executive Officer & Board Member
Aaron Michels MD Co-Founder & Chief Scientific Officer
Peter Gottlieb MD Co-Founder, Chief Medical Officer & Board Member
Jonathan Rigby Board Member & Independent Director
You’re viewing 4 of 9 executive team members. Get the full list »

IM Therapeutics Board Members (10)

Name Representing Role Since
Aaron Michels MD IM Therapeutics Co-Founder & Chief Scientific Officer 000 0000
Ed Orr IM Therapeutics Board Member 000 0000
Jason Dinges Ph.D Self Board Member 000 0000
Jonathan Rigby Self Board Member & Independent Director 000 0000
Nandan Padukone Ph.D IM Therapeutics Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

IM Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IM Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CU Healthcare Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
T1D Fund Venture Capital Minority 000 0000 000000 0
To view IM Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial